IPC
TVTX icon

Independent Portfolio Consultants’s Travere Therapeutics TVTX Stock Holding History

Independent Portfolio Consultants’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,345
Closed -$27K – 806
2015
Q3 		$27K Buy
+1,345
New +$39.8K 0.01% 658

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Independent Portfolio Consultants's TVTX Position: Q4 2015 in Review

Independent Portfolio Consultants sold out of Travere Therapeutics (TVTX) in Q4 2015, closing a stake of 1,345 shares — an estimated $27K sold.

Independent Portfolio Consultants first reported a position in TVTX in Q3 2015 and held it in 1 quarter. The position peaked at $27K in Q3 2015. 116 funds tracked by Wall St. Rank hold TVTX as of Q4 2015.

  • Independent Portfolio Consultants reported no remaining Travere Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Independent Portfolio Consultants sold 1,345 Travere Therapeutics shares in Q4 2015, an estimated $27K.
  • Independent Portfolio Consultants first reported a position in Travere Therapeutics in Q3 2015 and held it in 1 quarter.
  • Independent Portfolio Consultants's Travere Therapeutics position peaked at $27K in Q3 2015.
  • 116 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2015.

Based on Independent Portfolio Consultants's 13F filing for Q4 2015, filed 12 Jan 2016.